Member Info for PlantPower

Welcome BeKind - you may want to extend ur stay @ motel GDR....newsflow imminent (appreciate same for ODX as well - hopefully all PI’s will be rewarded).

PP

....find adds £7.5m to market cap of GDR.

Well done Jay - DB, buy that man a bottle from the top shelf.

Thanks Jay for the excitement - even if it’s only for the next hour or so (ahead of RNS).

PP

Let’s hope vol spike clears out mystery II Seller as well pre actual RNS(s)

101.7p paid

98p paid

97.2p paid

94.9 paid

MM’s grabbing shares - we all know newsflow imminent.

Don’t be fooled (or set stop losses at this juncture!)

PP

Hands up - who got a bargain top up / entry this morning!?!

I went 24 hrs too early! ;0)

PP

93.7p paid

By the way LP - I like hearing you use ‘supremely confident’..even on a red day!

Agreed - written ahead of approval so all documentation ready to fly one approval lands.

Wouldn’t want an RNS stating approval after an eternity but now we need to draft the launch pack docs ;0)

Isn’t it just the draft user manual ready to ping out to users / clients once approval lands?

Eg ducks aligned waiting starters firing gun.

We may never know how it truly unfolded....but if all goes as we hope, we will all be happy (GDR employees, II’s & PI’s) and can go on our merry way....

PP

Heavy selling today - appears over 100k+....3x10k reported late.

Let’s hope it’s an Acacia style own goal.....

PP

Repost from early Aug, but still believe to be true (today insignificant in bigger pic)...we’re making the right strategic moves to be a big player in the Covid testing market for the foreseeable future:

Right scaleable product
Right global strategic manufacturing partnerships
Right global strategic scaleable automated throughout partner
Right strategically targeted geographical areas
Right strategic distribution partners (more to come)
Right strategic forward looking CEO
Right strategic investment backing (GHIF)
Right strategic scaleable platform / product extension (POC)
Right sticky long term shareholders ;0)

#PeacePlantsPatienceProsper

I’ve wondered for a while now why Calculus has below ‘*’ on investor web page and rest don’t - maybe that’s a scoobydoo clue:

“ * - DATE OF LAST NOTIFICATION”

http://www.genedriveplc.com/investor-relations/shareholders.php

PP

Repost of change in guidance regarding lab testing circa Aug 20th:

“ the department has determined that the Food and Drug Administration ("FDA") will not require premarket review of laboratory developed tests ("LDT") absent notice-and-comment rulemaking, as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances. Those seeking approval or clearance of, or an emergency use authorization ("EUA") for an LDT may nonetheless voluntarily submit a premarket approval application, premarket notification or an EUA request, respectively, but are not required to do so, and FDA will adjudicate those submissions. Those opting to use LDTs in their laboratories without FDA premarket review or authorization may do so with the understanding that they would not be eligible for PREP Act coverage absent approval”

Not a lawyer but appear firms would lose element of immunity from liability - so again, without professing to know litigious ins/outs, would expect FDA EUA still required / preferable. But clearly optionality available if big pharma got comfortable with risk....

https://www.hhs.gov/coronavirus/testing/recission-guidances-informal-issuances-premarket-review-lab-tests/index.html

Agree @Dave77 - Mystery Seller & smaller mystery Buyer is ongoing saga.

I would add from end of July there was also circa 3.2m vol unaccounted for as well, so Seller may be closer to being below threshold.

I’m unsure but agree with bigAl, would plump for Calculus over GHIF. Strangely in calculus fund page it states below:

“ Shares were sold on the Alternative Investment Market (AIM) in June 2020, providing an exit for some investors.”

https://www.calculuscapital.com/cms/media/Calculus-EIS-Fund-21-IM.pdf

But apart from RNS late June regarding % change from GHIF bond conversion, I can’t see any other RNS. Could be misprint it’s meant to be July which would tie in with theory....although still no RNS, but maybe due to ongoing sale with under 3% soon..,

Clearly - it’s still...a mystery!

PP

Good question, It’s been discussed before but not straightforward - Labs can approve themselves, FDA EUA not required, but you would still expect it’s preferred.

Caveat - raised previously, not clear if that holds true where provider of test is not owned by lab, however...GDR test manufactured by Cytvia who are owned by same parent as BC....confused!?!

PP